Patients with EGFR exon 20 insertion mutations are difficult to treat or do not experience treatment response with commonly used therapies that target EGFR. How is amivantamab reshaping the landscape of lung cancer therapy? Find out in our latest In Focus feature.
The Symposium on Primary Breast Cancer in Older Women (1 March 2024; Nottingham, UK) has an overarching goal of optimizing the management of primary breast cancer in older women. Future Oncology is calling all breast cancer experts to submit their abstract for the next symposium. Find out more here.
EGFR mutations are one of the most common causes of NSCLC tumors. Preliminary data from the CHRYSALIS study suggests that amivantamab may hold promise for these patients. Explore the latest in EGFR lung cancer research with our video summary of this study.
An interdisciplinary team of researchers have created a method to produce more accurate 3D models of complex tumors, enabling researchers to test different therapeutic strategies in greater detail than before. Find out more from this news piece published on our sister site BioTechniques.
